ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

09 Apr 2024 17:30:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

07 Mar 2024 16:03:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

13 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

ALX Oncology Announces November Investor Conference Participation

01 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

10 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Pricing of Public Offering

05 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Proposed Public Offering

04 Oct 2023 16:10:18 By Nasdaq GlobeNewswire

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

03 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

02 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Realigns Executive Leadership Team

06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces September Investor Conference Participation

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

10 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

11 May 2023 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

09 May 2023 07:00:02 By Nasdaq GlobeNewswire

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

13 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

09 Mar 2023 16:01:00 By Nasdaq GlobeNewswire